Drugs / Angiomax
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | ANGIOMAX | — | 2005-06-13 – 2005-11-30 | fda.gov ↗ |
| Approved | US (FDA) | ANGIOMAX | — | 2000-12-15 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00073580 | Oct 2003 → Sep 2005 | heart disorder, thrombocytopenia, thrombotic disease | The Medicines Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Angiomax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073580 ↗ |
| Route | Intravenous | “intravenous (IV) bolus and 1.75 mg/kg/h IV infusion” NCT00073580 ↗ |